Citigroup Upgrades Genzyme (GENZ) to Buy
More News related to GENZ
- Biotech Can Still Be Healthy to Investors
- Study Shows Record $65 billion Spent by U.S. Biopharmaceutical Companies in R&D
- Genzyme (GENZ) and Isis Pharma (ISIS) Mipomersen Phase 3 Meets Primary Endpoint
- Mipomersen Phase 3 Study in HoFH Patients Featured in The Lancet
- EHSI Signs Option with Biotech Firm Celulas Genetica
More News related to Trader Talk
- Icahn Now Wants "All" of Lions Gate (LGF)
- Aon Consulting (AON) to Acquire Compensation and Benefit Strategies Division from J.P. Morgan (JPM)
- Icahn Announces Intent to Purchase All Shares of Lions Gate (LGF)
- Morningstar (MORN) Announces $52M Agreement to Acquire Realpoint LLC
- Diamond Foods (DMND) Receives Approval for Pending Acquisition of Kettle Foods; Guides Higher
Citigroup upgrades Genzyme (Nasdaq: GENZ) from Hold to Buy, but trims their price target from $64 to $63.
For more analyst ratings on GENZ click here.
Genzyme Corporation operates as a biotechnology company worldwide.
Related Categories
Trader TalkUpgrades
Stocks Mentioned
+1.98Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
